live, attenuated, dengue serotype 1, 2, 3, 4 virus

Vaccineexperimental

Dengue vaccine is a vaccine used to prevent dengue fever in humans. Development of dengue vaccines began in the 1920s but was hindered by the need to create immunity against all four dengue serotypes. As of 2023, there are two commercially available vaccines, sold under the brand names Dengvaxia and Qdenga. — Wikipedia

Clinical trial activity

41 trials · 21 clinical orgs · 0 marketing orgs

Phase 1
8
Phase 2
34
Phase 3
20
Phase 4
0

Earliest trial started Aug 1, 2003 (NCT00384670)

Timeline

2000s

  1. Jan 1, 2003

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2006

    Earliest Phase 2 Sponsor(trial)

2010s

  1. Jan 1, 2010

    Earliest Phase 3 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • dengue 1,2,3,4 (attenuated) vaccine
  • dengue fever vaccine
  • live, attenuated, dengue serotype 1, 2, 3, 4 virus
  • live, attenuated, recombinant dengue serotype 1, 2, 3, 4 virus
  • live attenuated tetravalent dengue fever vaccine
  • live attenuated tetravalent dengue vaccine
  • recombinant live attenuated trivalent dengue vaccine
  • tetravalent dengue vaccine
  • tetravalent dengue vaccine
  • tetravalent dengue vaccine candidate
  • tetravalent dengue vaccine (tvdv)
  • tetravalent live attenuated dengue vaccine

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07087912Phase 3Jan 1, 2026Butantan Institute, University of Sao Paulo
NCT06891950Phase 3Nov 30, 2025Butantan Institute, Fundação Butantan
NCT07047521Phase 3Nov 7, 2025Takeda
NCT06973772Phase 3Aug 31, 2025Butantan Institute
NCT06665035Phase 3Apr 30, 2025Takeda
NCT06579755Phase 3Mar 17, 2025Takeda
NCT06741683Phase 2/Phase 3 (Phase 3)Jan 31, 2025Takeda
NCT06060067Phase 3Feb 8, 2024Takeda
NCT03999996Phase 3Oct 1, 2019Takeda
NCT03771963Phase 3Mar 28, 2019Takeda
NCT03746015Phase 2Dec 28, 2018Takeda
NCT03342898Phase 3Feb 28, 2018Takeda
NCT03341637Phase 3Dec 14, 2017Takeda
NCT02948829Phase 2Apr 3, 2017Takeda
NCT02747927Phase 3Sep 7, 2016Takeda
NCT02406729Phase 3Feb 1, 2016Butantan Institute
NCT02433652Phase 1Sep 1, 2015Johns Hopkins University, National Institute of Allergy and Infectious Diseases (NIAID), University of Vermont
NCT02425098Phase 2Jun 3, 2015Takeda
NCT02302066Phase 2Dec 1, 2014Takeda
NCT02193087Phase 2Jul 1, 2014Takeda
Showing 20 of 41 trials
Page 1 / 3

Organizations

Research & Development (21)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
TakedaFor profit181832012
SanofiFor profit111122010
Sanofi-AventisFor profit6022010
Butantan InstituteAcademic/Hospital5422013
United States ArmyGovernment5422003
GlaxoSmithKlineFor profit4112003
Government of ThailandGovernment2012003
InviragenFor profit2112010
Banco Nacional de Desenvolvimento Economico e SocialGovernment1012013
Butantan FoundationAcademic/Hospital1012013
Department of DefenseGovernment1012013
Fundação ButantanAcademic/Hospital1012025
Fundação de Amparo à Pesquisa do Estado de São PauloAcademic/Hospital1012013
Johns Hopkins UniversityAcademic/Hospital1012015
National Institute of Allergy and Infectious Diseases (NIAID)Government1112015
National Institutes of Health (NIH)Government1012013
United States NavyGovernment1012011
Universidad de AntioquiaAcademic/Hospital1012010
University of Sao PauloAcademic/Hospital1112026
University of VermontAcademic/Hospital1012015
21 organizations
Page 1 / 2